tiprankstipranks
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
The Fly

ANDA filing for generic Firdapse not a surprise, says Piper Sandler

Piper Sandler analyst Joseph Catanzaro made no change to the firm’s Overweight rating and $20 price target on Catalyst Pharmaceuticals (CPRX) shares. Catalyst on Monday received notice that Teva (TEVA) submitted an ANDA filing to the FDA for generic Firdapse, which "should not have come as a surprise," given Catalyst had been clear that an ANDA filing could have been pursued as early as November 2022, the analyst tells investors in a research note. While there is a moving target on the remaining exclusivity period, the firm believes there remains sufficient opportunity to continue to recognize a revenue stream that would allow Catalyst to continue to diversify away from Firdapse.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CPRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles